Cognition Therapeutics Framtida tillväxt
Future kriterier kontrolleras 0/6
Cognition Therapeutics s intäkter förväntas minska med 30.4% per år medan dess årliga intäkter förväntas växa med 64.7% per år. EPS förväntas falla med 6.6% per år.
Viktig information
-30.4%
Tillväxttakt i vinsten
-6.62%
Tillväxttakt för EPS
| Pharmaceuticals vinsttillväxt | 14.4% |
| Intäkternas tillväxttakt | 64.7% |
| Framtida avkastning på eget kapital | n/a |
| Bevakning av analytiker | Low |
| Senast uppdaterad | 18 May 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Analysartikel • Mar 28
Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Ny berättelse • Mar 26
DLB Psychosis Program And Biomarker Strategy Will Shape Long Term Upside Potential
Catalysts About Cognition Therapeutics Cognition Therapeutics is a clinical stage biopharmaceutical company focused on developing zervimesine for neurodegenerative diseases such as dementia with Lewy bodies and Alzheimer's disease. What are the underlying business or industry changes driving this perspective?Analysartikel • Nov 12
We're Keeping An Eye On Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, Cognition...Analysartikel • Jul 04
We're A Little Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analysartikel • Dec 20
Cognition Therapeutics (NASDAQ:CGTX) Will Have To Spend Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Analysartikel • Sep 06
Can Cognition Therapeutics (NASDAQ:CGTX) Afford To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Jul 31
Cognition Therapeutics: Shines Less Bright After Phase 2 Results In Alzheimer's Disease
Summary Cognition Therapeutics' stock dropped over 40% after Phase 2 trial results for Alzheimer's disease. Results showed cognitive benefit but fading statistical significance over time. CT1812 did not outperform placebo on all rating scales over 3-6 months, raising concerns for future milestones and larger trials. Financial reliance on NIH grants poses risks, and ongoing trials in dementia with Lewy Bodies, Alzheimer's and dry AMD have the potential for further stock decline. Read the full article on Seeking AlphaAnalysartikel • May 22
Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Seeking Alpha • Apr 18
Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's
Summary Cognition Therapeutics is set to report topline data from its Phase 2 trial in Alzheimer's disease in mid-2024. CT1812, the company's lead drug candidate, is a sigma-2 receptor antagonist for Alzheimer's and aims to prevent the binding of toxic Aβ oligomers. Preliminary data from the ongoing SHINE trial showed some interesting results, but were not consistent with other previous studies, raising caution about the upcoming data. At a ~$70 million market cap with about half of that cash, the topline readout could be a binary event for the stock. Read the full article on Seeking AlphaAnalysartikel • Nov 30
Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Analysartikel • Aug 15
Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Analysartikel • Mar 17
Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Seeking Alpha • Sep 27
Cognition stock rises 12% on $2.14M grant from NIH for Alzheimer's study
Cognition Therapeutics (NASDAQ:CGTX) said it received a $2.14M grant from the National Institute on Aging (NIA) to help complete an ongoing study of CT1812 in adults with mild-to-moderate Alzheimer's disease. The study called SEQUEL will evaluate if CT1812 results in a normalization of the EEG patterns. The trial is enrolling 16 adults who will receive either CT1812 or placebo, the company said in a Sept. 27 press release. Cognition noted that the study is taking place at the Amsterdam UMC Dept. of Neurology/Alzheimer Center and Brain Research Center. The NIA, a division of the National Institutes of Health (NIH), awarded a $3.2M grant in 2020 to support the study and has now awarded $2.14M, the company added. CGTX +12.28% to $1.92 premarket Sept. 27Analysartikel • Aug 12
We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Aug 05
Cognition's Alzheimer's candidate demonstrates mechanism of action; shares soar
An analysis of biomarker data from Cognition Therapeutics' (NASDAQ:CGTX) Alzheimer's disease candidate CT1812 indicate the oral once-daily treatment supports a synaptoprotective mechanism of action and has a role in normalizing cellular processes. Proteomic analyses demonstrated CT1812's impact on several Alzheimer's biomarkers, including YKL-40, which is an indicator of inflammation and is upregulated in the disease. Results showed that participants given CT-1812 saw declining levels of YKL-40. The candidate also had a significant impact on cerebrospinal fluid levels of clusterin, a genetic risk factor for Alzheimer's. Cognition closed up 62% on Thursday but is down 16% in Friday premarket trading.Analysartikel • Mar 19
We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2028 | N/A | -103 | -91 | N/A | 1 |
| 12/31/2027 | N/A | -34 | -64 | N/A | 3 |
| 12/31/2026 | N/A | -32 | -58 | N/A | 4 |
| 3/31/2026 | N/A | -20 | N/A | N/A | N/A |
| 12/31/2025 | N/A | -23 | -25 | -25 | N/A |
| 9/30/2025 | N/A | -28 | -30 | -30 | N/A |
| 6/30/2025 | N/A | -33 | -31 | -31 | N/A |
| 3/31/2025 | N/A | -33 | -31 | -31 | N/A |
| 12/31/2024 | N/A | -34 | -28 | -28 | N/A |
| 9/30/2024 | N/A | -34 | -26 | -26 | N/A |
| 6/30/2024 | N/A | -31 | -23 | -23 | N/A |
| 3/31/2024 | N/A | -29 | -21 | -21 | N/A |
| 12/31/2023 | N/A | -26 | -16 | -16 | N/A |
| 9/30/2023 | N/A | -23 | -21 | -21 | N/A |
| 6/30/2023 | N/A | -23 | -17 | -17 | N/A |
| 3/31/2023 | N/A | -24 | -18 | -18 | N/A |
| 12/31/2022 | N/A | -21 | -19 | -19 | N/A |
| 9/30/2022 | N/A | -24 | -8 | -8 | N/A |
| 6/30/2022 | N/A | -22 | -10 | -10 | N/A |
| 3/31/2022 | N/A | -19 | -6 | -6 | N/A |
| 12/31/2021 | N/A | -16 | -4 | -4 | N/A |
| 9/30/2021 | N/A | -12 | -4 | -4 | N/A |
| 6/30/2021 | N/A | -10 | -3 | -3 | N/A |
| 3/31/2021 | N/A | -9 | -5 | -5 | N/A |
| 12/31/2020 | N/A | -12 | -3 | -3 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: CGTX förväntas förbli olönsam under de kommande 3 åren.
Resultat vs marknad: CGTX förväntas förbli olönsam under de kommande 3 åren.
Höga tillväxtresultat: CGTX förväntas förbli olönsam under de kommande 3 åren.
Intäkt vs marknad: CGTX förväntas inte ha några intäkter nästa år.
Hög tillväxtintäkter: CGTX förväntas inte ha några intäkter nästa år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: Otillräcklig data för att avgöra om CGTX s avkastning på eget kapital förväntas bli hög om tre år
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/22 04:37 |
| Aktiekurs vid dagens slut | 2026/05/21 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Cognition Therapeutics, Inc. bevakas av 7 analytiker. 4 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| William Wood | B. Riley Securities, Inc. |
| Mayank Mamtani | B. Riley Securities, Inc. |
| null null | B. Riley Securities, Inc. |